Myriad Genetics Provides Update on Discussions with UnitedHealthcare regarding Medical Policy for Pharmacogenetic Testing
Portfolio Pulse from
Myriad Genetics is in discussions with UnitedHealthcare regarding a new medical policy that restricts access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight test. The policy is set to take effect on January 1, 2025. Myriad is presenting additional clinical data to support its case.
December 10, 2024 | 11:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Myriad Genetics is negotiating with UnitedHealthcare over a policy that limits access to its GeneSight test. The outcome could impact Myriad's market access and revenues.
The new policy by UnitedHealthcare restricts access to Myriad's GeneSight test, potentially affecting Myriad's market access and revenues. The company's active engagement and presentation of additional data indicate the importance of this issue.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
NEUTRAL IMPACT
UnitedHealthcare's new policy restricts access to multi-gene panel pharmacogenetic tests, including Myriad's GeneSight. This could affect its relationships with genetic testing providers.
UnitedHealthcare's policy change may affect its relationships with genetic testing providers, but the direct financial impact on UNH is less clear compared to Myriad.
CONFIDENCE 85
IMPORTANCE 60
RELEVANCE 70